Mylan board faces pressure from pension funds

Investors, including the New York City and State pension funds and the California State Teacher’s Retirement System, are urging shareholders to vote against Mylan (NSDQ:MYL) chairman Robert Coury and 5 other board members at the company’s upcoming annual meeting.
Coury was compensated with more than $97 million last year and some investors aren’t happy about it. The pensions funds are major institutional shareholders – together, they control 4.3 million shares of the EpiPen-maker.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan board faces pressure from pension funds appeared first on MassDevice.

Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Mylan Teva Pharmaceuticals Source Type: news